TEVETEN

This brand name is authorized in Australia, Austria, Canada, Cyprus, Ecuador, Estonia, Finland, Germany, Hong Kong SAR China, Ireland, Lithuania, Malta, Netherlands, Poland, Singapore, South Africa, Turkey, UK.

Active ingredients

The drug TEVETEN contains one active pharmaceutical ingredient (API):

1	Eprosartan UNII 8N2L1NX8S3 - EPROSARTAN MESYLATE
	Eprosartan is a potent, synthetic, orally active non-biphenyl non-tetrazole angiotensin II receptor antagonist, which binds selectively to the AT1 receptor.
	Read more about Eprosartan

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09CA02	Eprosartan	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5491B, 8397Y, 8447N, 8951D
CA	Health Products and Food Branch	02240432, 02243942
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00577426, 00754532, 02585140, 11010390
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	3175-MEE-0318
EE	Ravimiamet	1010855, 1081101, 1081112, 1888140
FI	Lääkealan turvallisuus- ja kehittämiskeskus	000449
GB	Medicines & Healthcare Products Regulatory Agency	13975, 139918, 146636, 146639, 146643, 162733, 21711
HK	Department of Health Drug Office	48755
IE	Health Products Regulatory Authority	49420, 49422, 49468, 49480
LT	Valstybinė vaistų kontrolės tarnyba	1004295, 1006743, 1006744
MT	Medicines Authority	MA1507/02101
NL	Z-Index G-Standaard, PRK	48135, 54887
PL	Rejestru Produktów Leczniczych	100100885
SG	Health Sciences Authority	11807P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699820090173
ZA	Health Products Regulatory Authority	35/7.1/0372